Compare Abbott Laboratories (ABT) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Noble Corporation plc — how do they compare? Abbott Laboratories trades at $111.02 (market cap $187.95B), while Noble Corporation plc trades at $44.1 (market cap $7.10B). The key difference: Abbott Laboratories is far larger — about 26.5× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.5%). Which is the better fit depends on your goals.
| ABT | NE | |
|---|---|---|
Market Cap | $187.95B | $7.10B |
Sector | Health | Technology |
52-Week High | $136.62 | $54.37 |
52-Week Low | $82.57 | $26.61 |
Enterprise Value | $214.96B | $8.53B |
Dividend Yield | 2.32% | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Noble Corporation (NE) trades at $44.21, up 1.52% today, with a mixed technical and fundamental backdrop. The stock exhibits a bullish trend in moving averages but faces resistance near $45-$46. Recent Q2 2026 earnings of $0.01 per share missed expectations, though the company secured $200 million in new contracts and maintains a $6.8 billion backlog. Positive cash flow from operations of $952 million in 2025 supports financial stability, but net income declined year-over-year.
The outlook is cautiously optimistic, with a consensus price target of $46 offering modest upside. Key opportunities include strong contract backlog and operational cash flow, while risks involve earnings volatility, ongoing legal investigations, and competitive pressures in offshore drilling. Analyst sentiment is divided, with 31% buy ratings reflecting balanced optimism and caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
